What is Mylan Institutional LLC’s doxorubicin hydrochloride?
Mylan Institutional LLC markets doxorubicin hydrochloride as an injectable chemotherapy drug. Doxorubicin hydrochloride is an anthracycline used in a range of cancers, delivered by healthcare professionals under oncology treatment protocols.
Why does “Mylan Institutional LLC” appear on doxorubicin hydrochloride labels?
In the U.S., the name shown as the manufacturer/labeler (such as Mylan Institutional LLC) typically reflects the company responsible for the product labeling and distribution, even when the underlying drug substance is produced by contract manufacturers or through a broader corporate supply chain.
Is this the same drug as other doxorubicin hydrochloride products?
Yes. “Doxorubicin hydrochloride” is the active ingredient name. Different companies may sell their own branded/generic versions, but the therapeutic drug is the same (the formulation details can vary by manufacturer, including vial size and excipients).
Is doxorubicin hydrochloride under patent or exclusivity?
Doxorubicin hydrochloride is an older oncology medicine with generic versions widely available. Patent and exclusivity status depends on the specific marketed product version and its formulation. For up-to-date patent and market exclusivity tracking tied to specific drug listings, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
How should patients or clinicians think about switching between manufacturers?
Switching between doxorubicin hydrochloride products is generally managed as a change in drug product labeling/manufacturer rather than a change in the active chemotherapy agent. Dosing is usually calculated based on the same doxorubicin hydrochloride active ingredient standards, while clinicians still verify:
- vial concentration and presentation
- product handling/storage instructions
- compatibility with the intended infusion regimen
What side effects or safety concerns are most relevant for doxorubicin hydrochloride?
Common and well-known safety issues for doxorubicin hydrochloride include the risk of serious cardiotoxicity, myelosuppression (low blood counts), and mucositis or gastrointestinal effects. The specific monitoring plan (for example, baseline and follow-up heart assessments) is standard in doxorubicin-based regimens.
Where to find the exact product details for the Mylan Institutional LLC version
Because “doxorubicin hydrochloride” can be marketed in multiple strengths and vial presentations, the most reliable way to confirm the exact product (strength, NDC, formulation, labeling) is to check the prescribing information or the packaging for the specific Mylan Institutional LLC listing you have.
If you share the strength (e.g., mg/mL), vial size, or the NDC number printed on the label, I can help narrow to the exact product description and what to look for on the label.
Sources cited:
1. DrugPatentWatch.com